Literature DB >> 19684147

Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group).

Clifton O Bingham1, Christoph Pohl, Thasia G Woodworth, Sarah E Hewlett, James E May, Mahboob U Rahman, James P Witter, Daniel E Furst, C Vibeke Strand, Maarten Boers, Rieke E Alten.   

Abstract

OBJECTIVE: Traditional outcome measures in randomized controlled trials (RCT) include well-established response criteria as well as ACR EULAR responses using Disease Activity Score 44 (DAS44)/DAS28 to assess improvement; however, a measure to assess worsening of disease has yet to be developed. This special interest group (SIG) was established to develop an evidence-based, consensus-driven standard definition of "flare" in rheumatoid arthritis (RA).
METHODS: At OMERACT 8, the need for a standardized definition of RA flare was recognized; interested individuals developed a proposal to form a SIG. A literature review was performed to identify publications and abstracts with flare definitions applied in RA, JIA, and lupus RCT as well as concerning patient perspectives on disease worsening. A SIG was held at OMERACT 9 with breakout sessions for patients and investigators.
RESULTS: The RA flare SIG was attended by about 120 participants, including 11 patients. Patients and investigators held separate breakout sessions to discuss various aspects of disease worsening. The following consensus was obtained at OMERACT 9: a working definition of flare should indicate worsening of disease activity (88%), persistence, and duration as critical elements (77%), and consideration of change or increase in therapy (74%).
CONCLUSION: A working definition of RA flare was developed based on these votes: flare is any worsening of disease activity that would, if persistent, in most cases lead to initiation or change of therapy; and a flare represents a cluster of symptoms of sufficient duration and intensity to require initiation, change, or increase in therapy. Using this working definition, evaluation of candidate domains will be conducted via Delphi exercise and further informed by patient focus groups. Validation of candidate definitions in appropriate RCT will be required.

Entities:  

Mesh:

Year:  2009        PMID: 19684147     DOI: 10.3899/jrheum.090369

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  38 in total

1.  PAR(2) expression in peripheral blood monocytes of patients with rheumatoid arthritis.

Authors:  A Crilly; E Burns; M B Nickdel; J C Lockhart; M E Perry; P W Ferrell; D Baxter; J Dale; L Dunning; H Wilson; J S Nijjar; J A Gracie; W R Ferrell; I B McInnes
Journal:  Ann Rheum Dis       Date:  2012-01-30       Impact factor: 19.103

Review 2.  More than Just Minutes of Stiffness in the Morning: Report from the OMERACT Rheumatoid Arthritis Flare Group Stiffness Breakout Sessions.

Authors:  Ana-Maria Orbai; Serena Halls; Sarah Hewlett; Susan J Bartlett; Amye L Leong; Clifton O Bingham
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

3.  The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease.

Authors:  Elena Myasoedova; Arun Chandran; Birkan Ilhan; Brittny T Major; C John Michet; Eric L Matteson; Cynthia S Crowson
Journal:  Ann Rheum Dis       Date:  2015-01-30       Impact factor: 19.103

4.  Patient-self assessment of flare in rheumatoid arthritis: translation and reliability of the Flare instrument.

Authors:  Thomas Maribo; Annette de Thurah; Kristian Stengaard-Pedersen
Journal:  Clin Rheumatol       Date:  2015-01-13       Impact factor: 2.980

Review 5.  Patient reported outcomes in rheumatoid arthritis clinical trials.

Authors:  Ana-Maria Orbai; Clifton O Bingham
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

Review 6.  Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.

Authors:  Echoe M Bouta; Richard D Bell; Homaira Rahimi; Lianping Xing; Ronald W Wood; Clifton O Bingham; Christopher T Ritchlin; Edward M Schwarz
Journal:  Nat Rev Rheumatol       Date:  2018-01-11       Impact factor: 20.543

7.  Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Authors:  Susan J Bartlett; Skye P Barbic; Vivian P Bykerk; Ernest H Choy; Rieke Alten; Robin Christensen; Alfons den Broeder; Bruno Fautrel; Daniel E Furst; Francis Guillemin; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham
Journal:  J Rheumatol       Date:  2017-08-15       Impact factor: 4.666

8.  Ultrasound-detected activity in rheumatoid arthritis on methotrexate therapy: Which joints and tendons should be assessed to predict unstable remission?

Authors:  Iustina Janta; Lara Valor; Inmaculada De la Torre; Lina Martínez-Estupiñán; Juan Carlos Nieto; Juan Gabriel Ovalles-Bonilla; Julia Martínez-Barrio; Natalia Bello; Michelle Hinojosa; María Montoro; Carlos Manuel González; Javier López-Longo; Indalecio Monteagudo; Luis Carreño; Esperanza Naredo
Journal:  Rheumatol Int       Date:  2015-12-28       Impact factor: 2.631

9.  Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes.

Authors:  Katie Bechman; Lieke Tweehuysen; Toby Garrood; David L Scott; Andrew P Cope; James B Galloway; Margaret H Y Ma
Journal:  J Rheumatol       Date:  2018-09-01       Impact factor: 4.666

Review 10.  Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.

Authors:  Vivian P Bykerk; Elisabeth Lie; Susan J Bartlett; Rieke Alten; Annelies Boonen; Robin Christensen; Daniel E Furst; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; James E May; Pam Montie; Ana-Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia Woodworth; Clifton O Bingham; Ernest H Choy
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.